Company News
Arvinas Shares Jump 13% on FDA Approval
Arvinas shares surged up to 13% after FDA approved its breast cancer drug Veppanu (vepdegestrant).
Veppanu targets estrogen‑receptor positive, HER2‑negative, ESR1‑mutated advanced/metastatic breast ca
